Acumen Pharmaceuticals Inc
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
Why this colour
Red, because several substance risks are documented: the quarterly report as of September 30, 2026, carries a going-concern warning, cash would last only into early 2027 per the company, and the only clinical product failed on October 30, 2026. A secured loan of $26.6 million stands ahead of shareholders. That the stock trades below book equity is a price argument, not a quality verdict — how much of it ever reaches shareholders is open. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
Acumen Pharmaceuticals is a textbook case of the leftover-value trap: after the Alzheimer’s trial ALTITUDE-AD failed on October 30, 2026, the stock is worth only about $15.2 million, a fifth of its $78.6 million in cash. But $51.0 million in liabilities stand ahead of shareholders, including a secured loan, plus unquantified wind-down costs and a board that proposes the path forward. Not investment advice.
Pipeline
The only clinical program failed: ALTITUDE-AD (542 patients) showed no meaningful difference from placebo at 18 months at either dose, and sabirnetug is being discontinued (8-K of 10/30/2026). What remains is the preclinical EBD program with JCR, with a filing for first human trials previously targeted for mid-2027.
Liquidity
$78.6 million in cash and marketable securities as of 9/30/2026, down from $116.9 million at the end of 2025. Going-concern warning in the 10-Q: funds last into early 2027 per the company, not twelve months. A new runway after the trial shutdown is missing.
Debt
Secured loan from K2 HealthVentures with $26.6 million owed (9/30/2026), interest of at least 9.65 percent, default right on a material adverse event; in a liquidation, the lender is paid before shareholders.
Valuation
Market value of about $15.2 million ($0.21, 10/30/2026) versus $34.6 million in equity and $27.6 million in cash after all liabilities (9/30/2026). The discount reflects unquantified wind-down costs and the company’s undecided path.
Influence over the path
The board proposes the path — sale, merger, liquidation or carrying on; on a merger, asset sale or dissolution, shareholders typically only approve or reject; a shelf of up to $500 million has been effective since 10/28/2026, and the stock trades far below Nasdaq’s one-dollar threshold.
Worth Noting
Acumen made our research list through the Reddit hype scanner (2 mentions, ApeWisdom, recorded 10/31/2026) — one day after the trial readout and the drop from $2.29 to $0.21.
Market value calculated by us: 72,327,320 shares (10-Q cover, as of 10/21/2026) × $0.21 (close on 10/30/2026) ≈ $15.2 million; consistent with the fundamental data. The last price cited in a filing (S-3: $1.98 on 10/23/2026) predates the readout.
Per-share figures calculated by us from the 10-Q as of 9/30/2026: cash $78.6M ≈ $1.09, equity $34.6M ≈ $0.48, cash minus liabilities $27.6M ≈ $0.38 per share. Costs since 9/30/2026 and wind-down costs are not included.
Annual cash used in operating activities per the SEC’s XBRL data series (10-K); cash at each date as the sum of cash equivalents and short- and long-term marketable securities. The 10-Q as of 9/30/2026 was filed on time on 10/26/2026; no amendment (10-Q/A) exists.
IPO: 11,499,998 shares at $16.00 including the underwriters’ option, registration effective 6/30/2021 — per the 2024 annual report 10-K, Item 5 “Use of Proceeds.”
Analyst price targets (average $7.60, six “strong buy” ratings, data as of 11/01/2026) clearly do not fit the situation after 10/30/2026; the data do not show whether they were revised.
Stock Watch
This analysis is as of November 1, 2026. Stock Watch will tell you what's changed at ABOS since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.60 $ to 3.40 $ · Last price: 0.2101 $ (As of: October 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/30/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals Inc ABOS | 0.0 | – | -0.6 | -26,379.0 | – | -100.0 | 1.3 |
| Vertex Pharmaceuticals Inc VRTX | 141.4 | 33.3 | 25.7 | 55.0 | 38.1 | 9.6 | 33.1 |
| Regeneron Pharmaceuticals Inc REGN | 96.4 | 23.4 | 13.1 | 44.5 | 20.7 | 1.0 | 42.6 |
| Moderna Inc MRNA | 88.0 | – | 4.6 | -66.0 | -131.1 | -39.2 | 687.9 |
| argenx NV ARGX | 55.5 | 34.1 | 26.2 | 59.8 | 32.0 | 89.6 | 8.8 |
| BeiGene, Ltd. ONC | 41.9 | 66.1 | 33.8 | 88.9 | 19.1 | 40.2 | 18.0 |
| Revolution Medicines Inc RVMD | 39.8 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 225.0 |
| Royalty Pharma Plc RPRX | 37.0 | 36.4 | 20.8 | 95.8 | 100.3 | 5.1 | 85.4 |
| Genmab AS GMAB | 35.6 | 44.9 | 24.7 | 93.0 | 35.2 | -82.7 | 99.0 |
| Median of companies shown | 41.9 | 35.2 | 20.8 | 55.0 | 26.3 | 1.0 | 42.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 2 | -8 | -8 | -0.28 | -7 | -11 | 7 |
| 2020 | 1 | -8 | -7 | -0.26 | -7 | -19 | 44 |
| 2021 | 1 | -20 | -101 | -2.63 | -18 | 225 | 230 |
| 2022 | 0 | -45 | -43 | -1.06 | -35 | 189 | 197 |
| 2023 | 0 | -61 | -52 | -1.08 | -43 | 267 | 310 |
| 2024 | 0 | -114 | -102 | -1.71 | -86 | 182 | 239 |
| 2025 | 0 | -124 | -121 | -2.00 | -116 | 70 | 123 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.62 | – | 0 | -38.60 | -20,873.00 | -27 | -27 |
| 2025: Q1 | -0.40 | – | 0 | – | – | -34 | -34 |
| 2025: Q2 | -0.57 | – | 0 | – | – | -32 | -32 |
| 2025: Q3 | -0.37 | – | 0 | – | – | -31 | -31 |
| 2025: Q4 | -0.41 | – | 0 | -100.00 | – | -19 | -19 |
| 2026: Q1 | -0.29 | – | 0 | – | – | -24 | -24 |
| 2026: Q2 | -0.45 | 21.10 | – | – | – | -18 | -18 |
| 2026: Q3 | -0.35 | 5.40 | – | – | – | -27 | -27 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Earnings & Surprises
Momentum & Trend
- 21-EMA Trend
- Above 21-EMA Pullback
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Power Trend
- Stan Weinstein: Stage 2
Research
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.50 | -1.50 – -1.50 | 0 | 25.0% | 1 |
| 12/31/2027 | -1.51 | -1.71 – -1.37 | 0 | -0.9% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Geprüft am 01.11.2026 gegen die Quartalsberichte (10-Q) zum 30.09.2026, 30.06.2026, 31.03.2026 und 30.09.2025 sowie die Geschäftsberichte (10-K) für 2025 und 2024 von Acumen Pharmaceuticals: Die Begriffe „AI“, „artificial intelligence“, „machine learning“, „ML“, „generative AI“, „large language model“ und „algorithm“ kommen in keinem der sechs Berichte vor (Volltextsuche; einziger Scheintreffer ist das Wort „neurodegenerative“). Acumen entwickelt Antikörper gegen Alzheimer (sabirnetug, am 30.10.2026 nach verfehltem Studienziel eingestellt; EBD-Programm mit JCR), hat keinen Produktumsatz und beschreibt weder einen KI-Einsatz noch eine Bedrohung des Geschäftsmodells durch KI — damit „neutral“ (dokumentierter Negativ-Befund).
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-10-26 · 10-Q 2026-08-12 · 10-Q 2026-05-12 · 10-Q 2025-11-12 · 10-K 2026-03-26 · 10-K 2025-03-27
Rated on November 1, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year 14.3%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 86 m net cash
- Operating cash flow covers the profits of the last three years 31 m
- Return on capital at 15% or higher, or up versus two years ago -133.4%
- Insiders hold at least 10% or are net buyers 6.8%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -100.0%
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -172.4%
- ROCE > 15% -133.4%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
The company
About the Company
Acumen Pharmaceuticals, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt zielgerichtete Therapien zur Behandlung der Alzheimer-Krankheit.
- Employees
- 60
- Headquarters
- Newton, MA
- Address
- 1210-1220 Washington St., 02465 Newton, United States
- Phone
- 617 344 4190
- Website
- acumenpharm.com
- IPO Date
- 07/01/2021
- ISIN
- US00509G2093
Management
| Name | Title | Birth Year |
|---|---|---|
| Daniel J. O'Connell M.B.A. | CEO & Director | 1970 |
| James Doherty Ph.D. | President & Chief Development Officer | 1968 |
| Matt Zuga | CFO & Chief Business Officer | – |
| Grant A. Krafft Ph.D. | Co-Founder | – |
| Caleb E. Finch Ph.D. | Co-Founder | – |
| William L. Klein Ph.D. | Co-Founder | – |
| Russell Barton M.S. | Chief Operating Officer | 1959 |
| Kelly Carranza | Senior Vice President of Finance & Accounting and Corporate Controller | – |
| Alex Braun M.B.A. | VP & Head of Investor Relations | – |
| Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 10/30/2026 Acumen Pharmaceuticals, Inc. (ABOS): Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
- 10/26/2026 Acumen Pharmaceuticals, Inc. (ABOS): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 09/16/2026 Acumen Pharmaceuticals, Inc. (ABOS): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/12/2026 Acumen Pharmaceuticals, Inc. (ABOS): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.